Redx and Caris Life Sciences partner to accelerate Phase II trial of RXC004

UK clinical-stage biotech Redx Pharma (AIM: REDX) edged up 5% to 62.80 pence this morning, as it announced a partnership with Caris Life Sciences, a molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare.

The partnership will leverage Caris' comprehensive Whole Transcriptome Sequencing (WTS) and Whole Exome Sequencing (WES) platform assay, real-world data and its Right-In-Time (RIT) clinical trial solutions to enhance the speed of US accruals for Redx's Phase II trial for the investigational Porcupine inhibitor, RXC004, in genetically-selected patients with Wnt-ligand dependent microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Financial terms of the collaboration have not been disclosed.

Utilizing Caris' RIT clinical trial solution will help Redx match the right US patients to the Phase II trial based on both the individual patient's molecular tumor profile and the trial's eligibility requirements, ie, those whose cancers carry Ring Finger Protein 43 (RNF43) loss of function mutations or R-spondin (RSPO) fusions with MSS mCRC, and have progressed following therapy with current standard of care. Through the nationwide identification of eligible patients with the required genetic characteristics Caris' flexible enrolment model will enable rapid initiation of study treatment for RXC004 at its extensive network of US RIT trial sites, in addition to trial sites initiated by Redx.